Cayma, Peru Clinical Trials

A listing of Cayma, Peru clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 11 clinical trials
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

This study is evaluating the efficacy of acalabrutinib in combination with bendamustine and rituximab (BR) compared with placebo plus BR in subjects with previously untreated mantle cell lymphoma.

acalabrutinib
rituximab
bendamustine
cyclin d1
Research Site
 (4.6 away) Contact site
  • 1270 views
  • 24 Jul, 2021
  • +250 other locations
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer

Phase III, double-blind, randomised study assessing the efficacy of capivasertib + fulvestrant vs placebo + fulvestrant for the treatment of patients with locally advanced (inoperable) or metastatic HR+/HER2- breast cancer following recurrence or progression on or after AI therapy.

Research Site
 (4.6 away) Contact site
  • 50 views
  • 02 Aug, 2021
  • +223 other locations
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)

The purpose of this study is to assess the efficacy and safety of pembrolizumab in combination with concurrent chemoradiation therapy followed by either pembrolizumab with olaparib placebo (Arm 1) or with olaparib (Arm 2) compared to concurrent chemoradiation therapy followed by durvalumab (Arm 3) in participants with unresectable, locally advanced …

measurable disease
durvalumab
pemetrexed
metastasis
paclitaxel
Hospital Nacional Carlos Alberto Seguin Escobedo ESSALUD ( Site 0604)
 (3.9 away) Contact site
  • 51 views
  • 01 Aug, 2021
  • +187 other locations
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC

Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer (TNBC)

formalin-fixed paraffin-embedded
measurable disease
breast cancer
cancer
paclitaxel
Research Site
 (4.6 away) Contact site
  • 1387 views
  • 30 Jul, 2021
  • +309 other locations
A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)

The reason for the study is to find out if an experimental combination of an oral medication called osimertinib (TAGRISSO) when used in combination with chemotherapy is more effective than giving osimertinib alone for the treatment of locally advanced or metastatic non-small cell lung cancer. Some lung cancers are due …

epidermal growth factor
growth factor
epidermal growth factor receptor
tyrosine
recurrent non-small cell lung cancer
Research Site
 (4.6 away) Contact site
  • 811 views
  • 21 Jul, 2021
  • +171 other locations
Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC

This study compares rPFS in men with mCRPC treated with talazoparib plus enzalutamide vs. enzalutamide after confirmation of the starting dose of talazoparib in combination with enzalutamide.

Centro Medico Monte Carmelo SCRLtda
 (4.6 away) Contact site
  • 4293 views
  • 01 Aug, 2021
  • +502 other locations
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)

The purpose of this study is to assess the efficacy and safety of treatment with olaparib (MK-7339) in combination with pembrolizumab (MK-3475) in adults with previously treated, advanced (metastatic and/or unresectable) Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-positive solid tumors.

measurable disease
pembrolizumab
mk-3475
solid tumor
advanced cancer
Hospital Nacional Carlos Alberto Seguin Escobedo ESSALUD ( Site 3206)
 (3.9 away) Contact site
  • 16 views
  • 01 Aug, 2021
  • +148 other locations
Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC) Ovarian Cancer or Breast Cancer

To evaluate the efficacy of romiplostim for the treatment of CIT in patients receiving chemotherapy for the treatment of NSCLC, ovarian cancer, or breast cancer measured by the ability to administer on-time, full-dose chemotherapy

Research Site
 (3.9 away) Contact site
  • 5 views
  • 01 Aug, 2021
  • +173 other locations
D9319C00001- 1L OC Mono Global RCT

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of maintenance olaparib compared with placebo in BRCAwt participants with Stage III to IV high grade serous or endometroid ovarian cancer (including fallopian tube cancer or primary peritoneal cancer) who are in complete or …

measurable disease
peritoneal cancer
olaparib
interval debulking surgery
tumor debulking
Research Site
 (4.6 away) Contact site
  • 0 views
  • 22 Jul, 2021
  • +81 other locations
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer

This is a Phase III, randomized, double-blind, placebo-controlled, multi-center international study assessing the activity of durvalumab and chemotherapy administered prior to surgery compared with placebo and chemotherapy administered prior to surgery in terms of pathological complete response.

carboplatin/paclitaxel
EGFR
lung carcinoma
durvalumab
carboplatin
Research Site
 (4.6 away) Contact site
  • 251 views
  • 31 Jul, 2021
  • +318 other locations